Jennifer Moore is a seasoned Senior Key Account Director at Celltrion USA, where she leverages her extensive expertise in the pharmaceutical industry to drive sales and enhance market positioning for innovative therapies. With a strong focus on Contracting through a buy-and-bill sales model, Jennifer excels...
Jennifer Moore is a seasoned Senior Key Account Director at Celltrion USA, where she leverages her extensive expertise in the pharmaceutical industry to drive sales and enhance market positioning for innovative therapies. With a strong focus on Contracting through a buy-and-bill sales model, Jennifer excels in navigating the complexities of Community Oncology Centers, Physician Office Infusion Centers, and Integrated Delivery Networks (IDNs). Her specialty areas encompass a diverse range of therapeutic fields, including Oncology, Gastroenterology, Rheumatology, Infectious Disease, Vaccinations, DNA testing, and Allergy Immunotherapy.
Currently, Jennifer is spearheading the product launch of Vegzelma, a biosimilar to Avastin, a critical addition to Celltrion's portfolio. In this role, she develops comprehensive account strategies and actionable plans that align with the company's sales objectives, ensuring that the introduction of Vegzelma is met with enthusiasm and support from key stakeholders. By identifying local opportunities and crafting tailored strategies, Jennifer enhances the visibility and accessibility of Celltrion USA products, ultimately driving sales results and fostering long-term collaborative relationships.
Her adeptness in account management and business strategy, combined with her deep understanding of pharmaceutical sales dynamics, enables her to deliver on budget while achieving ambitious sales goals. Jennifer's commitment to excellence and her ability to navigate the intricacies of the healthcare landscape make her a pivotal figure in advancing Celltrion USA's mission to provide high-quality, accessible therapies to patients in need.
